within Pharmacolibrary.Drugs.ATC.N;

model N05AB03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.4,
    Cl             = 0.3333333333333333,
    adminDuration  = 600,
    adminMass      = 0.008,
    adminCount     = 1,
    Vd             = 0.01,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.011666666666666665,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Perphenazine is a typical antipsychotic drug from the phenothiazine class used primarily in the treatment of schizophrenia and severe nausea or vomiting. While widely used in the past, its use has declined in many countries with the advent of atypical antipsychotics, but it remains approved and available in several regions.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for an adult population based on available summary literature; no direct individual-based pharmacokinetic modeling publications identified.</p><h4>References</h4><ol><li>Stefano Spanarello, Teresa La Ferla,The pharmacokinetics of long-acting antipsychotic medications.,Current clinical pharmacology,2014<a href='https://pubmed.ncbi.nlm.nih.gov/23343447/'>https://pubmed.ncbi.nlm.nih.gov/23343447/</a></li><li>Parnian Mohammadi, Reza Mahjub, Mojdeh Mohammadi, Katayoun Derakhshandeh, Ali Ghaleiha, Mohammad Mehdi Mahboobian,Pharmacokinetics and brain distribution studies of perphenazine-loaded solid lipid nanoparticles.,Drug development and industrial pharmacy,2021<a href='https://pubmed.ncbi.nlm.nih.gov/33307865/'>https://pubmed.ncbi.nlm.nih.gov/33307865/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N05AB03;
